JP Morgan Chase
FBLG icon

JP Morgan Chase’s FibroBiologics FBLG Stock Holding History

JP Morgan Chase’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-968
Closed -$17.4K – 7728
2025
Q1 		$17.4K Buy
968
+318
+49% +$9.08K ﹤0.01% 6190
2024
Q4 		$26K Buy
650
+38
+6% +$2.04K ﹤0.01% 6195
2024
Q3 		$37.8K Buy
612
+70
+13% +$4.65K ﹤0.01% 6074
2024
Q2 		$54.1K Sell
542
-590
-52% -$113K ﹤0.01% 5825
2024
Q1 		$245K Buy
+1,132
New +$272K ﹤0.01% 5238

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's FBLG Position: Q2 2025 in Review

JP Morgan Chase sold out of FibroBiologics (FBLG) in Q2 2025, closing a stake of 968 shares — an estimated $17.4K sold.

JP Morgan Chase first reported a position in FBLG in Q1 2024 and held it in 5 quarters. The position peaked at $245K in Q1 2024. 57 funds tracked by Wall St. Rank hold FBLG as of Q2 2025.

  • JP Morgan Chase reported no remaining FibroBiologics position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 968 FibroBiologics shares in Q2 2025, an estimated $17.4K.
  • JP Morgan Chase first reported a position in FibroBiologics in Q1 2024 and held it in 5 quarters.
  • JP Morgan Chase's FibroBiologics position peaked at $245K in Q1 2024.
  • 57 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.